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Introduction
Solid tumors and their metastases require the process of angio-
genesis to invest themselves with host microvasculature and to 
undergo pathologic progression (Folkman, 1992). Blockade of 
this process leads to tumor arrest and apoptosis (Holmgren 
et al., 1995). Effective agents include proteolytic fragments of 
collagen XVIII (endostatin), platelet factor 4 (anginex), TNP-
470 (a fumagillin derivative), antibodies against integrins and 
proangiogenic growth factors (e.g., anti-VEGF antibodies), 
small-molecule inhibitors of endothelial growth-factor recep-
tors (e.g., VEGF, FGF, and PDGF receptor tyrosine kinase 
  inhibitors), and matrix metalloproteinase inhibitors (Folkman, 
1992; Carmeliet and Jain, 2000; Liekens et al., 2001; Ellis, 
2005). Many proangiogenic growth factors, in particular, 
FGF-2 and heparin-binding splice isoforms of VEGF-A, such 
as VEGF164, bind to heparan sulfate proteoglycans expressed on 
tumor endothelia or in the extracellular matrix, which facilitates 
formation of signaling complexes composed of the ligands and 
their receptor tyrosine kinases (Iozzo and San Antonio, 2001; Jiang 
and Couchman, 2003; Presta et al., 2005). The dependence 
of receptor activation on heparan sulfate suggests that endo-
thelial heparan sulfate might represent a therapeutic target and 
that inhibitors might have synergistic effects because of inter-
fer  ence with multiple growth factor signaling pathways important 
for tumorigenesis.
Binding of both FGF-2 and VEGF164 depends on the sul-
fation state of heparan sulfate, in particular N-sulfation of glu-
co  samine residues in specifi  c domains along the heparan sulfate 
chain (Yayon et al., 1991; Turnbull et al., 1992; Ono et al., 
1999). A family of four N-acetylglucosamine N-deacetylase/
N-sulfotransferases (Ndst) catalyze this reaction (Esko and 
Selleck, 2002), but microvascular endothelial cells only ex-
press Ndst1 and Ndst2 (Wang et al., 2005). Ndst2-defi  cient mice 
are essentially normal, aside from defective granule forma-
tion in   connective tissue-type mast cells (Forsberg et al., 1999; 
Humphries et al., 1999). In contrast, mice with a systemic dele-
tion of Ndst1 die perinatally because of forebrain defects, skeletal 
malformation, and lung hypoplasia (Ringvall et al., 2000; 
Grobe et al., 2005; Pan et al., 2006; Pallerla et al., 2007), but 
vasculogenesis and angiogenesis up to birth appear normal by 
gross examination and general histology. Here, we show that 
  altering Ndst1 expression in endothelial cells alters growth of 
syngeneic murine tumors because of a unique alteration in the 
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T
o examine the role of endothelial heparan sulfate 
during angiogenesis, we generated mice bearing 
an endothelial-targeted deletion in the biosyn-
thetic enzyme N-acetylglucosamine  N-deacetylase/
N-sulfotransferase 1 (Ndst1). Physiological angiogenesis 
during cutaneous wound repair was unaffected, as was 
growth and reproductive capacity of the mice. In contrast, 
pathological angiogenesis in experimental tumors was 
  altered, resulting in smaller tumors and reduced micro-
vascular density and branching. To simulate the angiogenic 
environment of the tumor, endothelial cells were isolated 
and propagated in vitro with proangiogenic growth 
factors. Binding of FGF-2 and VEGF164 to cells and to puri-
ﬁ   ed heparan sulfate was dramatically reduced. Mutant 
endothelial cells also exhibited altered sprouting responses 
to FGF-2 and VEGF164, reduced Erk phosphorylation, 
and an increase in apoptosis in branching assays. 
Corresponding changes in growth factor binding to tumor 
endothelium and apoptosis were also observed in vivo. 
These ﬁ   ndings demonstrate a cell-autonomous effect of 
heparan sulfate on endothelial cell growth in the context 
of tumor angiogenesis.
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tumor microvasculature. In contrast, the mutation had no effect 
on physiological angiogenesis, e.g., during cutaneous wound 
repair. The change in tumor angiogenesis appears to result from 
altered binding and signaling by the proangiogenic growth fac-
tors FGF-2 and VEGF.
Results
Physiological angiogenesis is unaffected 
by altering Ndst1 expression 
in endothelial cells
To determine the role of Ndst1 in angiogenesis in adult animals, 
mice harboring a conditional loxP-flanked allele of Ndst1 
(Ndst1
f/f) were crossed with transgenic mice expressing the 
  bacteriophage recombinase Cre under the control of the angio-
poietin receptor (Tek) promoter, which is expressed in a pan-
endothelial fashion (Constien et al., 2001; Kisanuki et al., 2001). 
Ndst1
f/fTekCre
+ (mutant) and Ndst1
f/fTekCre
− (wild type) mice 
were recovered at the expected Mendelian frequency and 
showed the normal pattern of weight gain, indicating that vasculo-
genesis and physiological angiogenesis were suffi  cient for nor-
mal development. Adult mutant mice were indistinguishable 
from their wild-type littermates in general health, behavior, and 
body weight (Wang et al., 2005). Ndst1
f/fTekCre
+ females also 
reproduced normally and had normal litter sizes, indicating that 
suffi  cient reproductive angiogenesis occurred to allow for nor-
mal colony propagation.
Physiological angiogenesis during cutaneous wound re-
pair also appeared normal. After a biopsy punch wound of dorsal 
skin, an intense angiogenic response was detected 3–4 d after 
injury at the granulating edges of healing wounds. Both mutant 
and wild-type mice showed a similar response in clustering of 
CD31-positive processes at the wound margin (Fig. 1 a). No sig-
nifi  cant difference in the density of processes at the wound edges 
was noted between the two groups (Fig. 1 b). Vascular density 
fell with distance from the wound margin in a similar fashion in 
both mutant and wild-type mice as well. The rate of wound con-
traction over the 4-d period also did not differ (Fig. 1 c), and in 
separate experiments, complete resolution of wounds occurred 
in both groups of mice by 10 d. Analysis of retinal vascular 
  development under normoxic conditions showed only a very 
minor effect that was not signifi  cant (Friedlander, M., personal 
communication). These fi  ndings suggest that physiological angio-
genesis was unaffected by endothelial inactivation of Ndst1.
Tumor growth is reduced 
in Ndst1
f/fTekCre
+ mice
To study the effect of inactivation of Ndst1 on pathological 
 angiogenesis, syngeneic Lewis lung carcinoma (LLC) cells were 
injected subcutaneously in the hindquarters of Ndst1
f/fTekCre
+ 
and Ndst1
f/fTekCre
− mice. As shown in Fig. 2 a, growth of sub-
cutaneous tumors in mutant animals was signifi  cantly attenuated 
(P < 0.001) relative to that observed in wild-type littermates 
at 10 and 15 d after injection. This effect was also seen in a sec-
ond transplant model in which syngeneic mouse melanoma 
(B16BL6) tumors were injected subcutaneously. Like LLC 
  tumors, melanoma exhibited a marked reduction in mean tumor 
volume in mutant mice compared with wild-type littermates at 
10 d (52% reduction in mean volume; P < 0.02). Because skin 
ulceration occurred and the animals showed signs of morbidity 
after 15 d, all tumor growth experiments were terminated as 
  required by Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) guidelines for the humane 
treatment of animals.
Because the TekCre transgene is expressed in endothelial 
cells, leukocytes, and marrow-derived endothelial precursors 
(Constien et al., 2001; Kisanuki et al., 2001), we performed 
bone marrow transplantation experiments to determine the rela-
tive contributions of these cell populations to the phenotype. 
Mutant mice transplanted with wild-type marrow showed per-
sistent attenuation in tumor growth, indicating that deletion of 
Ndst1 in tissue-resident endothelia was suffi  cient to achieve a 
marked alteration in tumor growth (Fig. 2, compare a and b, 
center). Transplantation of wild-type mice with mutant marrow 
did not alter tumor growth (Fig. 2 b, right), indicating that alter-
ation of heparan sulfate in marrow-derived cells had no effect. 
Control transplantations in which the genotype of the marrow 
donor and the recipient mouse were matched showed the ex-
pected results (Fig. 2 b, left). These experiments exclude factors 
such as altered tumor immunity because of changes in leuko-
cyte heparan sulfate. Histological examination of the tumors 
Figure 1.  Wound healing and angiogenesis is not affected in Ndst1-
  deﬁ  cient mice. Mice were subjected to a 3-mm-diameter full-thickness punch 
lesion on the dorsal skin area. (a) After 4 d, biopsies were taken for 
immuno  histology with CD31 mAb to detect blood vessels in the wound 
  region   (arrows). Wounds in both wild-type and mutant mice underwent sub-
stantial angiogenesis, as noted by the high density of CD31+ processes 
detected along the dermis. (b) Density of microvasculature at punch-biopsy 
wound border, as measured by mean number of CD31+ microvessels per 
400× microscopic ﬁ  eld surrounding the wound center, is shown for each 
genotype (mean density calculated from four ﬁ   elds taken about wound 
center for each mouse; n = 8 mice per group). No signiﬁ  cant difference 
was noted between mutant and wild-type mice (P = 0.96). (c) Contraction 
of the wound area during healing was measured daily. No signiﬁ  cant dif-
ferences were observed between mutant and wild-type mice (P = 0.288). 
Anatomic structures in panel a include the wound ﬁ  brin plug (FP), located 
to one side of the original wound margin (represented by the dotted red 
line), bordered by a proliferating epithelial (Ep) layer and dermis (D). Error 
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also showed that tumor infi   ltration by CD45/Gr-1–positive 
granulocytes was not statistically different in the mutant, sug-
gesting that reduced acute leukocyte infi  ltration caused by al-
tered endothelial heparan sulfate (Wang et al., 2005) did not 
affect tumor growth. These fi  ndings also exclude effects due 
to marrow-derived endothelial precursors, which can serve as 
early contributors to vascularization in some tumors (Lyden 
et al., 2001; Shinde Patil et al., 2005).
Tumor microvasculature in mutant mice 
is altered
To determine whether the decrease in tumor mass was caused 
by a change in tumor microvasculature, we examined the pat-
tern of staining of CD31 (PECAM-1 [platelet/endothelial cell 
adhesion molecule-1]) in tumor sections (Fig. 3). Microvascular 
density was signifi  cantly reduced in tumors grown on the mutant 
background (Fig. 3 b; 26.8 ± 4.7 vs. 35.3 ± 4.7 microvessels 
per 400× fi  eld in mutant and wild-type mice, respectively; 
P < 0.02). A slight increase in vessel caliber was also apparent 
when antibody binding was visualized by fl  uorescence micros-
copy (Fig. 3 b).
To obtain greater morphometric detail, intravital micros-
copy was used to assess microvascular branching, density, skel-
etal length, and caliber in LLC tumor spheroid preparations 
implanted on dorsal skinfold chambers. Views of tumor micro-
vasculature at 12 d after implantation revealed a general reduc-
tion in vascular density and complexity within tumors grown in 
the mutant (Fig. 3 c). Morphometric analysis of digitized im-
ages showed a marked reduction in degree of branching, density 
of linearized vasculature (grid intersection), and skeletal length 
(Fig. 3, d and e). A small, but statistically signifi  cant (P < 0.02) 
increase in vascular caliber was noted as well. These alterations 
may have resulted from a primary branching defect of tumor 
neovasculature (Parsons-Wingerter et al., 2000) and are similar 
to changes in vascular development after in vivo treatment 
with anti-VEGF antibodies or VEGF receptor tyrosine kinase 
inhibitors (Yuan et al., 1996; Jain, 2003) and alterations in 
FGF- dependent bud formation and branching morphogenesis of 
respiratory epithelium during Drosophila melanogaster tracheal 
development (Lin et al., 1999) and vertebrate lung development 
(Izvolsky et al., 2003).
Altered binding of FGF-2 and VEGF164 
to endothelial heparan sulfate
To gain insight into the mechanism underlying the alteration in 
tumor vascularization, we attempted to purify endothelial cells 
from tumors and normal tissues. However, we were unable to 
obtain suffi  cient numbers of cells from tumors, and the cultures 
were overtaken rapidly by small numbers of contaminating tu-
mor cells. In contrast, highly purifi  ed cells were obtained from 
lungs and livers of mutant and wild-type mice. These cells pro-
liferated for two to three passages in culture, and each popula-
tion maintained their differentiated phenotype based on CD31 
expression (Fig. 4 a), positive staining for von Willebrand Factor, 
and uptake of DiI-labeled acetylated low-density lipoprotein 
(Wang et al., 2005). Both mutant and wild-type endothelial 
cells grew at comparable rates in culture (in medium supple-
mented with heparin, endothelial cell growth supplement, and 
20% FBS; Fig. 4 b). Omission of heparin from the growth medium 
mildly decreased growth of both mutant and wild-type cells. 
Thus, isolated cells showed no obvious effect of Ndst1 defi  -
ciency on proliferation in monolayer culture.
The extent of deletion of the Ndst1
f/f allele in endothelial 
cells from TekCre
+ mice was >95%, as measured by quantita-
tive PCR, consistent with values obtained by Southern blotting 
(Wang et al., 2005). Examination of expression of Ndst1-4 
  expression by quantitative RT-PCR showed >95% reduction in 
Ndst-1 message in mutant cells, without any signifi  cant change 
in expression of Ndst2-4 (unpublished data). Analysis of di-
saccharides liberated from heparan sulfate by heparinase degrada-
tion showed a reduction of N-sulfated units, leading to an overall 
2.3-fold reduction in glucosamine N-sulfate (Fig. 4 c). Residual 
N-sulfation presumably arose from the action of Ndst2 (Ledin 
et al., 2006). Because of the dependence of downstream O-sulfo-
transferases on N-sulfation (Esko and Selleck, 2002), the de-
gree of glucosamine 6-O-sulfation and uronyl-2-O-sulfation of 
Figure 2.  Tumor growth is reduced in Ndst1
f/fTekCre
+ mutant 
mice. (a) LLC (4 × 10
5 cells) were injected into the hindquarters 
of either Ndst1
f/fTekCre
+ or Ndst1
f/fTekCre
− mice (n = 5 per 
group). Tumor volume was estimated by caliper measurements at 
the indicated times. (b) To control for the genotype of hemato-
poietic tissue among the various mice, mutant (n = 5) and wild-
type (n = 7) mice were transplanted with bone marrow from 
genotype-matched mice (b, left). A separate group of mutant mice 
(n = 5) was transplanted with wild-type marrow (b, middle), and 
a group of wild-type mice was transplanted with mutant bone 
marrow (b, right). Tumor growth consistently tracked with the 
  genotype of the recipient mouse, indicating that differences in 
heparan sulfate in the host endothelium were responsible for the 
altered growth of the tumors. Error bars indicate SD.JCB • VOLUME 177 • NUMBER 3 • 2007  542
chains was reduced as well (Fig. 4 c). The change in heparan 
sulfate structure led to a decrease in cell-surface binding of 
FGF-2 and VEGF164 to mutant endothelia compared with cells 
derived from wild-type animals (Fig. 4 d). In contrast, binding 
of EGF, which does not require heparan sulfate, was unaffected 
by the mutation. Binding of FGF-2 and VEGF164 to 
35S-radio-
labeled heparan sulfate isolated from the mutant endothelia was 
reduced as well (Fig. 4 e).
Altered signaling responses of mutant 
endothelial cells to FGF-2 and VEGF164
Under standard culture conditions, wild-type and mutant pri-
mary endothelia proliferated at similar rates and to the same 
 extent (Fig. 4 b), but striking differential growth responses of cells 
were observed when cells were cultivated on Matrigel and sup-
plemented with FGF-2 or VEGF164. Wild-type endothelia prolif-
erated and formed extensive branched networks in response to 
1–10 ng/ml FGF-2, whereas mutant cells were unresponsive 
(Fig. 5, a and b). Increasing the concentration of FGF-2 to val-
ues in excess of the physiological range (100 ng/ml) was suffi  -
cient to stimulate a sprouting response by mutant cells (Fig. 5 b, 
right), indicating that they expressed functional FGF receptors 
that were not activated at lower doses of FGF-2. Treating wild-
type cells with heparinase, which degrades heparan sulfate, 
mimicked the phenotype of the mutant (Fig. 5 c). The addition 
of unfractionated heparin also blocked the response, whereas 
it had no effect on mutant cells (even at low concentration). 
  Mutant cells also failed to respond to VEGF164, whereas wild-
type cells sprouted robustly in response to this factor (Fig. 5 d). 
Infecting endothelial cells derived from Ndst1
f/fTekCre
− mice 
with Adenoviral-Cre yielded comparable results (unpublished 
data), indicating that the effect was cell autonomous and not the 
result of selection of unresponsive cells during their cultivation.
When mutant cells failed to sprout on Matrigel, the cells 
remained predominantly clustered and harbored frequent apop-
totic cells (Fig. 6 a), consistent with the idea that the alteration 
in heparan sulfate led to decreased growth responses through 
the relevant receptor tyrosine kinases (FGFR1, FGFR2, and 
VEGFR2). Western blotting studies with antibodies showed no 
change in receptor expression (unpublished data). Addition of 
FGF-2 to wild-type endothelia resulted in marked phosphoryla-
tion of Erk1/2 after 10 min of stimulation, and the signal was 
sustained for 60 min (Fig. 6 b, top). Mutant endothelial cells, 
however, exhibited about a threefold reduction in signaling at 
both time points. VEGF-dependent Erk1/2 phosphorylation was 
even more dramatically affected. Wild-type cells responded ro-
bustly by 10 min, and the signal declined by 60 min. In contrast, 
mutant cells were essentially unresponsive to VEGF (Fig. 6 b, 
bottom). Treatment of wild-type cells with heparinase caused 
similar effects (unpublished data). FGF-2 and VEGF had only 
a modest effect of phosphorylation of PKB/Akt in either wild-
type or mutant cells  (Fig. 6 c).
Figure 3.  Visualization of altered tumor microvasculature in 
Ndst1
f/fTekCre
+ mice. (a) After 15 d, tumor sections were pre-
pared and stained with CD31 mAb (examples of vessels are 
indicated by black arrowheads). (b) Vessels were stained with 
anti-CD31 mAb and visualized by ﬂ  uorescence microscopy 
as well. (c) Intravital videomicroscopy of tumor vascular 
  morphology. Representative photomicrographs of tumor spher-
oid microvasculature 12 d after implantation into skinfold 
chambers are shown for wild-type (top) and mutant (bottom) 
spheroids. (d) Representative digitized images of spheroid 
microvasculature from four independent mice. The ﬁ  rst image 
in each set corresponds to the photomicrographs shown in 
panel c. (e) Digitized images of four to six regions per cham-
ber were recorded at 100× magniﬁ  cation and scanned and 
quantiﬁ   ed for microvascular branching, grid intersection, 
  linear skeletal length, and caliber. Error bars indicate SD. 
Bars, 100 μm.ENDOTHELIAL HEPARAN SULFATE AND TUMOR ANGIOGENESIS • FUSTER ET AL. 543
Decreased growth factor binding to tumor 
endothelium in vivo
To determine whether the altered responses of endothelial cells 
in vitro corresponded to changes in growth factor binding in 
vivo, the distribution of FGF-2 and VEGF was measured in 
  tumor sections. Immunohistochemical analysis of endogenous 
FGF-2 in tumors showed diffuse staining throughout the tissue 
regardless of genotype (unpublished data). Incubation of sam-
ples with biotinylated FGF-2 also showed a diffuse distribution 
of binding sites throughout the tumor stroma. However, close 
inspection of the vasculature revealed intense staining in the 
perivascular zones in tumors from wild-type mice, a region rich 
in basement membrane–type heparan sulfate proteoglycans 
(Fig. 7 a, solid arrowheads; Iozzo, 2005). In contrast, tumors 
from mutant animals showed a marked reduction in staining 
(Fig. 7 a, open arrowheads), consistent with decreased binding 
to endothelial cell–derived heparan sulfate (Fig. 4, d and e).
In contrast to endogenous FGF-2, we were able to ex-
amine the localization of endogenous VEGF in the tumor micro-
vasculature using GV39M mAb, which binds to complexes 
between VEGF-A and its major signaling receptor VEGFR-2/
fl  k-1 (Brekken et al., 1998; Joyce et al., 2005). Immunofl  uores-
cence of tumor sections from wild-type mice demonstrated a 
subset of vessels that stained strongly (Fig. 7 b, top). Many of 
these vessels also stained for laminin, consistent with studies 
that showed VEGF in association with basement membranes in 
some vascular beds (Brekken, R., personal communication). 
Vessel-associated GV39M was localized in a predominantly ab-
lumenal orientation relative to CD31 (Fig. 7 c), supporting the 
idea that endothelial VEGFR-2 engages VEGF from the stromal 
side of the vessel (Qu-Hong et al., 1995; Brekken and Thorpe, 
2001). Mutant tumor sections stained less strongly with GV39M 
mAb, especially in laminin-associated vessels (Fig. 7 b, bottom). 
Interestingly, the distribution of laminin, which also binds 
  heparan sulfate, was not grossly affected. Pericyte investment, 
as detected by mAb against smooth muscle cell actin, also was 
not signifi  cantly affected by the mutation (Fig. 7 d). Combined 
CD31/TUNEL staining of tumor sections from mutant mice re-
vealed several apoptotic nuclei associated with walls of the micro-
vasculature that were not present in wild-type tumors (Fig. 7 e), 
consistent with the in vitro data presented in Fig. 6.
Because the Ndst1 defi  ciency affected vessel-associated 
VEGF–VEGFR-2 complexes (Fig. 7 b), we examined whether 
tumor growth depended on VEGFR-2 expression. When LLC 
tumors were grown in VEGFR-2 heterozygous mice, mean tu-
mor volumes were reduced by  50% compared with the wild 
type (P < 0.0001; Fig. 7 f). CD31-stained tumor sections from 
VEGFR-2 mutants also exhibited reduced microvascular den-
sity (33% reduction relative to wild type; P < 0.03) and in-
creased vessel caliber (Fig. 7 g) similar to that described for 
tumors grown in Ndst1
f/fTekCre
+ mice (Fig. 3).
Discussion
We have demonstrated that altering Ndst1 expression in endo-
thelial cells results in decreased tumor angiogenesis and tumor 
growth. Vascular changes in the tumor included decreased ves-
sel density and branching and increased caliber of the remaining 
vessels. These changes correlated with diminished endothelial 
process formation in vitro in response to FGF-2 and VEGF165, 
altered growth factor binding to isolated endothelial cells and 
heparan sulfate, and attenuation of Erk1/2 signaling. Altering 
endothelial heparan sulfate decreased the association of FGF-2 
and VEGF with the tumor vasculature in vivo and increased endo-
thelial apoptosis in both branching assays as well as the tumor 
vasculature. These fi  ndings correlate changes in endothelial cell 
growth mediated by FGF-2 and VEGF to decreased vasculariza-
tion of the tumor, which in turn diminished tumor growth.
Recently, Jakobsson et al. (2006) showed that VEGF sig-
naling in endothelial cells and angiogenesis were fully supported 
by heparan sulfate expressed in trans by adjacent perivascular 
smooth muscle cells. Given the selective deletion of Ndst1 in 
endothelial cells in Ndst1
f/fTekCre
+ mice and the fact that pericyte 
density was unaltered (Fig. 7 d), it would appear that pericyte 
Figure 4.  Binding of FGF-2 and VEGF164 to Ndst1 mutant microvascular 
endothelia is reduced. Primary lung microvascular endothelia were iso-
lated from Ndst1
f/fTekCre
+ or Ndst1
f/fTekCre
− mice (Materials and methods). 
(a) Flow cytometry of cells with CD31 mAb showed a high degree of 
  purity. Control incubations contained isotype-matched IgG as primary anti-
body. (b) Proliferation of mutant versus wild-type primary endothelia in cell 
culture. Fluorescence in the assay is directly proportional to number of via-
ble cells. Measurements for each time point were performed in triplicate, 
and the values represent the mean ± SD. (c) The extent of glucosamine 
N-sulfation, uronyl 2-O-sulfation, or glucosamine 6-O-sulfation was deter-
mined by disaccharide analysis of heparan sulfate isolated from mutant 
and wild-type endothelial cells. (d) Binding of biotinylated FGF-2, VEGF165, 
and EGF to isolated wild-type (dark gray proﬁ   les) and mutant (unﬁ  lled 
black curve) endothelial cells. Controls consisted of cells treated only with 
streptavidin-FITC (light gray proﬁ  les). (e) Equal amounts of growth factor 
were added to puriﬁ  ed heparan [
35S]sulfate isolated from mutant and wild-
type endothelial cells, and complexes were collected by membrane ﬁ  ltration. 
Binding of growth factor in the presence of heparin (+Hep) is shown as a 
control. Error bars indicate SD.JCB • VOLUME 177 • NUMBER 3 • 2007  544
heparan sulfate will not substitute for endothelial heparan sulfate 
during tumor angiogenesis. Thus, in the context of tumor vascu-
lature, endothelial heparan sulfate behaves in a cell-autonomous 
manner. Ideally one would like to further potentiate the phenotype 
by more dramatic changes in heparan sulfate composition or con-
tent. However, complete ablation of sulfation (Ndst1
−/−Ndst2
−/−) 
or inhibition of the polymerase that catalyzes formation of the 
heparan sulfate chains (Ext1/Ext2) result in early developmental 
defects, including failure to differentiate mesoder  mal precursors 
of the endothelium (Lin et al., 2000; Holmborn et al., 2004; 
Stickens et al., 2005), thus preventing further studies of the vas-
culature in adult animals.
Vasculogenesis (endothelial cell differentiation/de novo 
vessel formation) and physiological angiogenesis appear to be 
unaffected in Ndst1
f/fTekCre
+ mice based on normal birth 
weight, growth of the animals, reproductive capacity, and nor-
mal cutaneous wound healing (Fig. 1). Nevertheless, endo-
thelial cells derived from the lungs of mutant animals showed 
alterations in growth factor binding, signaling, and sprouting 
behavior under conditions that promote proliferation in vitro 
(Figs. 4–6). Why, then, was angiogenesis selectively altered in 
the tumor environment but not under conditions of cutaneous 
wound repair? One possibility is that the tumor microenviron-
ment places an especially high demand on the tumor vascular 
bed with respect to transfer of nutrients, removal of waste 
products, and gas exchange. If correct, then further stress, e.g., by 
hypoxia or induced tissue regeneration, might reveal underlying 
differences in angiogenic capacity in normal tissues. Alterna-
tively, the composition of growth factors might differ in the 
wound environment, or other glycosaminoglycans, such as der-
matan sulfate, which is abundant in wound tissue, might com-
pensate for reduced heparan sulfate in the endothelium (Penc 
et al., 1998; Taylor et al., 2005). Further studies are needed to 
address this point.
As observed in other tumor models, the microvascula-
ture in LLC tumors displayed a highly chaotic morphology 
compared with normal vasculature (Carmeliet and Jain, 2000; 
Jain, 2005). Altering heparan sulfate specifi  cally in the endothe-
lium resulted in less branched and tortuous tumor vessels and de-
creased overall density of the neovasculature (Fig. 3). Similar 
morphological changes have been observed in tumor micro-
vasculature after in vivo treatment with anti-VEGF antibodies 
or VEGF receptor tyrosine kinase inhibitors (Yuan et al., 
1996; Jain, 2003), suggesting that altering heparan sulfate in 
the endothelium may preferentially affect VEGF-mediated 
  responses. Other observations that support this idea include 
the following: (1) transfection of VEGF nullizygous tumor 
cells with VEGF164 rescues tumor growth and vascular density/
branching, whereas altered tumor growth and a hypobranched/
hypodense vasculature results from transfection with the non–
heparin binding isoform, VEGF120 (Grunstein et al., 2000); 
(2) mouse embryos engineered to express only VEGF120 exhibit 
a marked decrease in capillary branching accompanied by in-
creased vascular caliber (Ruhrberg, 2003); (3) altering Ndst1 
expression reduces the formation of VEGF–VEGFR com-
plexes in mutant tumor vasculature (Fig. 7 b); and (4) reduc-
tion of expression of VEGFR2 in heterozygous mutants 
resulted in reduced tumor growth and vascularization (Fig. 7, 
f and g). The modest dilatation of mutant tumor microvascula-
ture that we observed could refl  ect incomplete inactivation of 
VEGF signaling, as the defi  ciency in Ndst1, although nearly 
fully penetrant, does not completely reduce sulfation of the 
heparan sulfate chains (Fig. 4 e).
The potentiation of growth factor action by heparan sul-
fate proteoglycans is thought to depend on formation of ternary 
complexes in which the heparan sulfate chain acts as a scaffold 
to approximate ligand and receptor, thus affecting signaling 
  intensity and duration (Forsten-Williams et al., 2005). In the 
  extracellular matrix, heparan sulfate proteoglycans also act as 
reservoir for growth factors (Vlodavsky et al., 1990), providing 
stability and enhancing the capacity for gradient formation 
(Lander et al., 2002). Many tumors secrete heparanase, which 
Figure 5.  Altered sprouting of Ndst1-deﬁ  cient microvascular 
endothelial cells on reconstituted extracellular matrix. (a) Wild-
type endothelial cells formed extensive networks of inter-
connected processes when plated on Matrigel with FGF-2 
at 10 ng/ml (top). Under the same conditions, sprouting of 
mutant cells was markedly impaired (bottom). Bar, 200 μm. 
(b) Process formation by wild-type cells varied with concentra-
tion of FGF-2, whereas mutant cells showed essentially no 
sprouting under these conditions. Treatment with saturating 
levels of growth factor (100 ng/ml) was sufﬁ  cient to restore 
sprouting by mutant cells. (c) Sprouting by wild-type cells 
to 10 ng/ml FGF-2 was inhibited by the addition of either 
3 mU/ml heparinase or 100 μg/ml heparin, whereas the 
marginal sprouting by mutant cells was unaffected. Data are 
mean values ± SD for net length of endothelial processes per 
(100×) microscopic ﬁ  eld, normalized to the response of un-
stimulated wild-type cells. (d) Mutant cells were also insensi-
tive to 10 ng/ml VEGF164. Data are the mean ± SD of three 
independent experiments normalized to the response of un-
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can degrade the extracellular matrix and liberate bound growth 
factors (Elkin et al., 2001; Vlodavsky et al., 2002), and over-
expression of heparanase in tumor cells results in enhanced 
angio  genesis and tumor growth (Zcharia et al., 2004). Because 
endothelial cells produce matrix proteoglycans, loss of Ndst1 
activity could, in theory, result in reduced storage of growth 
factors in the surrounding matrix. Thus, reduced tumor growth 
in Ndst1
f/fTekCre
+ mice could refl  ect a combination of cell-
autonomous growth factor signaling defects as well as reduced 
availability of growth factors in the matrix.
Heparan sulfate chains do not exist as free polysaccha-
rides but, rather, occur covalently bound to proteoglycan core 
proteins. The major heparan sulfate proteoglycans in endo-
thelial cells consist of the glycosylphosphatidylinositol-linked 
glypicans, membrane-spanning syndecans, and secreted proteo-
glycans (perlecan, agrin, and collagen XVIII). Some of these 
have roles in angiogenesis based on mutational studies. Mutants 
defective in syndecan-1 show an increase in vessel length dur-
ing corneal angiogenesis, possibly because of differences in re-
lease of infl  ammatory mediators (Gotte et al., 2002), whereas 
overexpression of syndecan-1 causes abnormal angiogenesis 
during cutaneous wound repair (Elenius et al., 2004). In con-
trast, syndecan-4 defi  ciency impairs fetal vessels in the placen-
tal labyrinth (Ishiguro et al., 2000) and angiogenesis during 
wound repair (Echtermeyer et al., 2001). Deletion of exon 3 of 
perlecan core protein, which bears a major heparan sulfate con-
taining domain, impairs wound angiogenesis as well as tumor 
angiogenesis (Zhou et al., 2004). Mice lacking collagen XVIII 
show delayed regression of blood vessels postnatally in the vit-
reous along the surface of the retina and abnormal outgrowth of 
retinal vessels (Fukai et al., 2002) but enhanced intimal neovas-
cularization in atherosclerotic aortas (Moulton et al., 2004). The 
variation in phenotype in mutants and tissues may refl  ect differ-
ences in the expression of individual proteoglycans in diverse 
vascular beds, other functional domains within the core proteins 
(O’Reilly et al., 1997; Bix and Iozzo, 2005), or changes in hepa-
ran sulfate in the supporting tissue in systemic mutants rather 
than cell-autonomous effects on endothelial cells. Additional 
studies are needed to analyze the effect of altering specifi  c proteo-
glycans selectively in endothelial cells.
Our fi  ndings validate heparan sulfate and the enzymes 
involved in its biosynthesis as potential targets for chemother-
apeutic intervention. Targeting heparan sulfate could prove 
  advantageous over strategies that focus on individual pro-
angiogenic growth factors, such as VEGF (e.g., bevacizumab; 
Bergsland, 2004), as heparan sulfate can modulate the activity 
of multiple angiogenic factors (e.g., hepatocyte growth factor, 
PDGF, heparin-binding EGF, angiopoietin, tumor necrosis 
factor-α, interleukin-8, and others; Blackhall et al., 2001; Jiang 
and Couchman, 2003), most of which bind to heparan sulfate. 
Previous studies have shown that tumor cell proliferation also 
depends on heparan sulfate (for review see Fuster and Esko, 
2005). Because heparan sulfate biosynthesis in endothelial 
cells and tumor cells utilizes a common set of enzymes, agents 
that target heparan sulfate would provide a two-prong approach 
for blocking both tumor cell division and formation of the sup-
porting vasculature.
Materials and methods
Cell lines and cell culture
LLC LL/2 (CRL-1642; American Type Culture Collection) was grown in 
DME (Invitrogen) containing 1.5 g/l sodium bicarbonate and supple-
mented with 10% FBS (HyClone). B16BL6 murine melanoma cell line was 
a gift from I. Fidler (University of Texas MD Anderson Cancer Center, 
Houston, TX) and was grown in MEM (Invitrogen) and supplemented 
with 7% FBS. Murine lung microvascular endothelial cells were isolated 
from mice essentially as described previously (Marelli-Berg et al., 2000), 
except after straining, cells were mixed with 4.8 ml 17% Nycodenz 
Figure 6.  Altered growth factor signaling by Ndst1-deﬁ  cient microvascular 
endothelia. (a) TUNEL assay was performed on mutant and wild-type endo-
thelial cells undergoing sprouting on Matrigel. In these experiments, 
cells derived from Ndst1
f/fTekCre
− mice were infected with Ad-Cre (Ndst1
f/f
Ad-Cre) or Ad-GFP virus as a control (Ndst1
f/f Ad-GFP). After infection with 
Ad-Cre, numerous apoptotic bodies were observed within the cell clusters 
(bottom, arrows). Ad-GFP–infected cells formed extensive sprouting net-
works that were relatively free of apoptotic bodies, and the few nonsprout-
ing clusters that were present also were devoid of apoptotic bodies (top 
right, inset). Bars, 100 μm. (b) Phosphorylation of Erk (p44/p42) in re-
sponse to the growth factors FGF-2 or VEGF164 was measured by Western 
blotting. The bands were scanned, the intensity of the phosphorylated pro-
tein was normalized to the intensity of the nonphosphorylated protein, and 
the ratio was scaled to the value obtained at t = 0 (values in parentheses). 
Total Erk was similar in mutant and wild-type cells. No signiﬁ  cant variation 
in signal intensity >60 min was observed in the absence of growth factor 
in mutant and wild-type endothelia. (c) Phosphorylation of Akt was mea-
sured in wild-type and mutant cells.JCB • VOLUME 177 • NUMBER 3 • 2007  546
(Sigma-Aldrich) in Gey’s balanced salt solution, overlaid with 1 ml PBS 
(Dulbecco and Vogt, 1954), and centrifuged at 1,400 g, and the endothe-
lial rich band was collected. Cells were then labeled with rat anti–mouse 
CD31 (0.2 μg/10
6 cells; Caltag), incubated with goat anti–rat antibody 
conjugated to magnetic beads, and passed over a magnetic column (Miltenyi 
Biotec) followed by washing, and puriﬁ  ed endothelia were eluted from the 
column into gelatin-coated plates. Cells were maintained one or two pas-
sages in DME supplemented with 20% FBS, 100 μg/ml endothelial growth 
supplement (Sigma-Aldrich), 100 μg/ml heparin (Scientiﬁ  c Protein Labora-
tories), and nonessential amino acids (Invitrogen). Culture media were 
supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin. 
All cells were maintained under an atmosphere of 5% CO2 and 100% 
  humidity at 37°C. Cell proliferation was examined using the Cell Titer-Blue 
viability assay (Promega) on primary endothelia. Cells were plated at 
5,000 cells/well in 96-well plates, grown in complete medium, and assayed 
on successive days for ﬂ  uorescence (excitation 488 nm/emission 575 nm; 
CytoFluor II ﬂ  uorimeter) after addition of Cell Titer-Blue reagent according 
to the manufacturer’s instructions. Fluorescence is proportional to the num-
ber of viable cells.
Animals
C57Bl/6 mice harboring a conditional mutation in exon 2 of Ndst1 
(Ndst1
f/f) were crossed with transgenic mice expressing Cre recombinase 
under control of the Tek (Tie2 receptor) promoter/enhancer (TekCre
+; Kisanuki 
et al., 2001; Wang et al., 2005). Ndst1
f/f TekCre
+ males were mated with 
Ndst1
f/f TekCre
− females generating equal numbers of mutant and wild-
type animals. Genotyping of mice was performed by PCR using genomic 
DNA from tail biopsies as described previously (Wang et al., 2005). Mice 
heterozygous for VEGFR-2 (VEGFR-2
+/−) were purchased from The Jackson 
Laboratory, with genotyping performed using primers as described previ-
ously (Shalaby et al., 1995). All animals were fully backcrossed on 
C57Bl/6 background (>10 generations). Mice were housed under barrier 
conditions in AAALAC-approved vivaria, following standards and proce-
dures approved by the local Institutional Animal Care and Use Committee. 
They were weaned at 3 wk, maintained on a 12-h light–dark cycle, and 
fed water and standard rodent chow ad libitum.
Quantitative PCR
To assess the efﬁ  ciency of Ndst1 inactivation, quantitative real-time PCR 
(Applied Biosystems) on genomic DNA was performed using primers ﬂ  ank-
ing the downstream loxP recombination site of the Ndst1 ﬂ  oxed construct 
(Grobe et al., 2005; n = 3 per group). Cycle threshold values from dupli-
cate assays were used to determine the initial starting quantity of loxP DNA 
from mutant versus wild-type genomic DNA samples.
To examine endothelial Ndst1-4 mRNA, total RNA was isolated 
from mutant versus wild-type primary lung endothelia, reverse trans  cri-
bed (Superscript III; Invitrogen), and amplified using gene-specific 
  intron-  spanning primers (primer sequences: Ndst1 forward, G  G  A  C  A  T  C  T  G  G-
T  C  T  A  A  G  , and reverse, G  A  T  G  C  C  T  T  T  G  T  G  A  T  A  G  ; Ndst2 forward, T  G  G  T  C  C  A-
A  G  G    A  G  A  A  A  A  C  C  T  G  , and reverse, G  G  T  A  C  G  A  C  C  T  C  C  G  A  G  T  C  A  A  A  ; Ndst3 
forward, C C  A  C  T  G  C  C  T  T  G  T  G  T  C  , and reverse, G G  A  G  T  A  C  G  C  T  C  G  G  T  C  ; Ndst4 
forward, C  T  A  A  C  T  A  C  T  T  C  C  A  C  T  C  , and reverse, A  T  G  T  G  C  A  C  T  G  C  A  T  A  C  C  ). 
Cycle threshold values from triplicate assays were used to calculate fold 
expression compared with expression of β-actin in the same sample.
Tumor growth studies
Tumor cells were harvested with Trypsin/EDTA (Invitrogen) and were inocu-
lated subcutaneously at 4 × 10
5 cells per mouse in 50 μl DME into the left 
hindquarters of 10–12 wk-old mice. Tumor growth was measured using 
calipers over a 15-d period, and tumor volume was estimated using the fol-
lowing formula: vol = length × (width)
2/2. Mice were killed after 15 d 
(beyond which tumor ulceration became frequent), and their tumors were 
dissected, measured directly with calipers, and removed for cryo- and for-
malin ﬁ  xation for further histologic analysis. Mouse bone marrow trans-
plantation studies were performed as previously described (Wang et al., 
2005). In a pilot experiment, all nontransplanted irradiated mice died 
within 1 wk. Conversely, all mice that underwent marrow transplantation 
survived until termination of the tumor experiment without ill appearance.
Immunohistochemical analysis of tumor microvasculature
Formalin-ﬁ  xed and deparafﬁ  nized embedded sections from 15-d subcuta-
neous tumors were stained with hematoxylin/eosin. Labeling of tumor vas-
culature was performed using rat anti–mouse CD31 (1:200; BD Biosciences) 
Figure 7.  Altered growth factor binding to tumor micro-
vasculature in Ndst1
f/fTekCre
+ mice. (a) Binding of biotinylated 
FGF-2 to histologic sections of LLC tumors. Solid arrowheads 
in wild-type sections (top) indicate strong binding in perivas-
cular locations (surrounding birefringent red blood cells within 
vessels) compared with sections from mutant mice (bottom, 
open arrowheads). (b) Binding of GV39M to VEGF–VEGFR2 
complexes and laminin mAb to vessels in tumor sections. In 
wild-type mice (top), GV39M (red ﬂ  uorescence) colocalized 
with vessel-associated laminin (green), as demonstrated in 
merged images (yellow). Sections from mutant mice (bottom) 
did not show vascular colocalization of complexes with laminin. 
(c) Tumor sections from wild-type mice costained with CD31 
mAb and GV39M (red) showed that the VEGF–VEGFR 
complexes were located ablumenal to CD31 staining (green). 
(d) Tumor sections from wild-type and mutant mice were 
stained for smooth muscle actin (brown) to assess the degree 
of vascular investment by pericytes. Mean density of stained 
processes among tumors in wild-type versus mutant back-
grounds was comparable (n = 5 mice per group; P = 0.3). 
(e) Vascular endothelium-associated apoptosis in tumors was 
examined by labeling for CD31 (blue) and TUNEL (brown). 
Vasculature in tumors from mutant mice showed occasional 
vessel-associated apoptotic bodies (right, arrowheads), 
whereas any TUNEL reaction in wild-type sections was only 
associated tumor nuclei (left, arrowhead). (f) Growth of tu-
mors on a VEGFR2 heterozygous background. LLC tumors 
were grown on the hindquarters of wild type as well as 
VEGFR2
+/− mice. Tumor volumes at 15 d are shown as scat-
ter plots for wild type (n = 11 mice; solid circles) and VEGFR2 
heterozygous mutants (n = 12 mice; open circles), with mean 
values indicated by horizontal bars on the graph. (g) Tumor 
microvasculature stained by anti-CD31 mAb (red) in VEGFR2 
mutant sections was also altered (right) relative to wild type 
(left). Bars: (a, d, and g) 50 μm; (b) 15 μm; (c and e) 20 μm. ENDOTHELIAL HEPARAN SULFATE AND TUMOR ANGIOGENESIS • FUSTER ET AL. 547
and biotinylated goat anti–rat secondary antibody (1:100; BD Biosciences) 
and detected using HRP-conjugated streptavidin (1:500; Jackson Immuno-
Research Laboratories). Development with AEC chromogen (Vector 
  Laboratories) was followed by counterstaining with Mayer’s hematoxylin. 
Microvascular density on tumor sections was quantiﬁ  ed by examining the 
number of vessels per 400× microscopic ﬁ  eld over ﬁ  ve ﬁ  elds per section. 
Fluorescence staining was performed using biotinylated secondary anti-
bodies and treatment with Cy3-conjugated streptavidin (1:500; Jackson 
ImmunoResearch Laboratories) on frozen tumor sections. In a separate 
  experiment, sections were incubated with rabbit anti-vWF antibody (Dako-
Cytomation), and bound antibodies were detected using HRP-conjugated 
anti–rabbit antibody (1:100; Jackson ImmunoResearch Laboratories) fol-
lowed by AEC chromogen/Mayer’s counterstain. Microvasculature was 
quantiﬁ  ed by a pathologist blinded to slide identiﬁ  cation. Staining of tumor 
leukocytes and smooth muscle actin was accomplished on parafﬁ  n-embedded 
sections exposed to biotin-conjugated rat anti–mouse CD45 antibody 
(1:200; BD Biosciences) or rabbit anti–mouse SmA antibody (1:50; Neo-
Markers), respectively, with secondary antibodies, development, and counter-
staining as described above. Density of SmA-positive processes was 
quantiﬁ   ed for each tumor section by calculating the mean number of 
stained vessels per 400× ﬁ  eld among six ﬁ  elds per section. Fluorescence-
stained tumor microvasculature was examined in cryopreserved tumor 
specimens by acetone ﬁ  xation of frozen sections, exposure to anti-CD31 mAb, 
biotinylated secondary antibodies, and treatment with Cy3-conjugated 
streptavidin (1:500; Jackson ImmunoResearch Laboratories). Vascular 
endothelial apoptosis in tumor sections was measured on acetone-ﬁ  xed 
frozen sections treated with anti-CD31 mAb, biotinylated secondary anti-
bodies, and AP-conjugated streptavidin followed by development with Vector 
Blue AP Substrate kit (Vector Laboratories) according to the manufacturer’s 
instructions. Colabeling with TUNEL was performed on the same sections 
(In Situ Cell Death Detection kit; Roche) and developed using AEC chromogen 
(Vector Laboratories) according to the manufacturer’s instructions.
In situ microvascular FGF-2 reactivity was assessed on frozen tissue 
sections by incubating specimens with biotinylated FGF-2 (Bai et al., 
1999), and bound factor was detected with HRP-conjugated streptavidin 
(1:500; Jackson ImmunoResearch Laboratories). For detection of VEGF–
VEGFR2 complexes, acetone-ﬁ  xed frozen sections were labeled with bio-
tinylated GV39M antibody (1:50; East Coast Biologics) followed by 
treatment with Cy3-conjugated streptavidin (1:500; Jackson Immuno-
Research Laboratories). Laminin in the same sections was visualized by treat-
ment with rabbit anti-laminin antibody (1:500; DakoCytomation) followed 
by FITC-labeled goat anti–rabbit antibody (1:50; Chemicon).
All microscopy for immunohistology was performed using a 
  microscope (Axiolab; Carl Zeiss MicroImaging, Inc.) with 20× (Plan-
  Neoﬂ  uar/0.5), 40× (Achroplan/0.65), or 100× oil (Plan-Neoﬂ  uar/1.30) 
objectives, with all image acquisition taken at room temperature. A 3CCD 
camera (DKC 5000; Sony) was used for digital image acquisition and 
captured using NIH ImageJ (Scion Image v. 1.60) software. Image process-
ing and storage (TIFF format) was performed using Photoshop software 
(Adobe). All ﬂ   uorescence images were captured using epiﬂ  uorescence 
(source for excitation was FluoArc [Carl Zeiss MicroImaging, Inc.]) with 
appropriate barrier ﬁ  lters on the same microscope system and using ﬂ  uoro-
chromes applied to tissues/cells as described.
Intravital studies of tumor angiogenesis
LLC LL/2 cells were resuspended in 10 ml complete medium at (2 × 10
6 
cells/ml) and were rocked in a 50-ml silicon-coated ﬂ  ask on a gyratory 
shaker in culture. After 48–72 h, tumor spheroids of similar diameters 
(600–1,000 μm) were selected, washed in serum-free medium, and indi-
vidually placed into dorsal skinfold chambers using a sterile plastic pipette 
as previously described (Borgstrom et al., 1996). Observations of tumor 
angiogenesis were made day 12 after tumor spheroid implantation in mu-
tant and wild-type mice as described previously (Manegold et al., 2003). 
Unanesthetized mice were placed in a plexiglass tube containing a longitu-
dinal slit from which the chamber projected for exposure to the microscope. 
The tube was immobilized on a plexiglass platform, which was placed on 
the stage of an intravital microscope (Biomed; Leitz) for viewing the tumor 
spheroid microcirculation. Images for all mice were recorded at room tem-
perature through a silicone intensiﬁ   ed tube camera (SIT68; DAGE-MTI) 
attached to the microscope (Nikon) using 4× or 10× water-immersion 
  objectives. The camera was connected to a monitor (Panasonic) and an S-VHS 
video recorder (HC-6600; JVC). For each chamber, the tumor spheroid vas-
culature was identiﬁ  ed using a 4× objective, and regions of highest tumor 
vascular density were recorded with the 10× objective. Still images of four 
to six tumor spheroid ﬁ  elds per chamber were recorded at 100× magniﬁ  -
cation and scanned for grid intersection using a 12 × 12 grid overlay that 
overlies the image, and branch points per ﬁ  eld were measured using Photo-
shop CS2. Digitized images were also analyzed on Volocity 2.6.1 software 
(Improvision), which was used to obtain total linear (skeletal) length of vas-
culature per ﬁ  eld, as well as mean vascular caliber per ﬁ  eld.
Mouse wound induction and contraction
Under general anesthesia, mice were wounded using a 3-mm-diameter full-
thickness dorsal skin punch biopsy. Wounds were then photographed daily 
over 4 d after injury, and wound area was measured using ImageJ software. 
The wounds were biopsied to include the margin to normal surrounding 
skin and snap-frozen in Tissue-Tek OCT (Sakura), and median sections 
were taken to include the wound ﬁ  brin plug at center, ﬂ  anked by the wound 
granulation tissue and surrounding normal dermis/epidermis. Acetone-
ﬁ  xed sections were incubated with biotinylated anti–mouse CD31 (1:100; 
BD Biosciences), followed by HRP-conjugated streptavidin (1:500; Jackson 
ImmunoResearch Laboratories). Wound microvascular density for any given 
mouse was then determined by calculating the mean number of CD31+ 
processes per 400× ﬁ  eld using four ﬁ  elds surrounding the wound center.
FGF-2 and VEGF164 binding to mutant endothelial cells and heparan sulfate
Primary lung endothelial cells were harvested at the ﬁ  rst or second passage 
using 5 mM EDTA in PBS. The cells were treated with heparin (1 mg/ml 
in PBS), washed with PBS, and incubated with biotinylated 0.6 μg/ml 
FGF-2 in buffer (0.5% BSA/2 mM EDTA in PBS) at 4°C for 1 h with gentle 
stirring on an orbital shaker (Bai et al., 1999). Bound FGF-2 was detected 
by ﬂ  ow cytometry using streptavidin-phycoerythrin. A set of cells was ex-
posed only to streptavidin-phycoerythrin as a negative control. To detect 
VEGF binding, cells (4 × 10
6/ml) were incubated for 1 h at 4°C with re-
combinant human biotinylated VEGF165 (1.1 μg/ml in PBS; R&D Systems). 
Bound VEGF165 was detected with avidin-FITC reagent (1:1,000; R&D 
  Systems) and ﬂ  ow cytometry. As controls, some cells were incubated with 
an irrelevant biotinylated protein (soybean trypsin inhibitor) or Alexa Fluor 
488–conjugated EGF (Invitrogen; each at 8 μg/ml for 45 min at 4°C) 
  followed by ﬂ  ow cytometry.
Primary lung endothelia were labeled for 48 h with 37 μCi/ml 
H2
35SO4 (655 Ci/mmol; NEN Life Science Products) in reduced-sulfate 
  medium (Ham’s F12 containing 10% dialyzed, ﬁ  lter-sterilized FBS). Isolation 
of puriﬁ  ed heparan [
35S]sulfate from cultured cells was performed essen-
tially as described previously (Bame and Esko, 1989). Binding of 0.2 μg 
FGF-2 and 1 μg VEGF164 was measured using a nitrocellulose ﬁ  lter binding 
assay using 5,000 cpm per assay (Kreuger et al., 2003). Controls included 
competition with 100 μg/ml heparin or use of bovine serum albumin in 
place of growth factor.
[
3H]Heparan sulfate was prepared from primary endothelial cells by 
culturing them in growth medium containing [6-
3H]glucosamine and 1 mM 
reduced glucose. Radiolabeled chains were degraded with heparinases 
and analyzed by anion-exchange HPLC as described previously (Toyoda 
et al., 1997).
Angiogenesis assays on reconstituted extracellular matrix
Murine lung endothelial cells were isolated from 8–12-wk-old mutant mice 
or their wild-type littermates as described previously (Wang et al., 2005). 
Purity was assessed by ﬂ  ow cytometry using CD31 mAb (FACSCalibur; BD 
Biosciences), uptake of DiI-acetylated-LDL (10 μg/ml; Biomedical Technol-
ogies), and reaction with polyclonal antibody to von Willebrand factor 
(DakoCytomation).
Matrigel (BD Biosciences) was added to each well of a 96-well plate 
and allowed to polymerize at 37°C for 1 h. Mutant or wild-type cells at ﬁ  rst 
or second passage were harvested with trypsin/EDTA (BioWhittaker) and 
resuspended in DME/20% FBS. Cells (5,000/well) were then added to 
duplicate wells in 100 μl of growth medium in the presence or absence of 
recombinant FGF-2 (Invitrogen) or murine VEGF164 (Calbiochem). In a sep-
arate experiment, additional wells were seeded in the presence or absence 
of heparinase at 0.3 mU/ml (heparin lyase III; Seikagaku) and 10 ng/ml 
FGF-2. After 48 h, the degree of endothelial sprouting over the gel surface 
was measured by determining the net lengths of endothelial processes (in 
duplicate wells) viewed under phase-contrast light microscopy. The data is 
reported as fold stimulation relative to baseline growth without added 
growth factor. In some experiments, 100 μg/ml of unfractionated heparin 
(Scientiﬁ  c Protein Laboratories) was added to the wells during the sprout-
ing period.
SDS-PAGE and Western blotting
Primary lung endothelial cells were seeded at equal density on gelatin-
coated 12-well culture dishes immediately after harvest from the animals 
and allowed to grow to near conﬂ  uence under standard culture conditions. JCB • VOLUME 177 • NUMBER 3 • 2007  548
After incubation for 4 h in serum-free DME without supplements, cells were 
exposed to FGF-2 or VEGF164 (10 ng/ml) for 10–60 min. Samples were 
solubilized and mixed with an equal volume of 125 mM Tris-HCl, pH 6.8, 
4% SDS, 20% glycerol, 100 mM dithiothreitol, and 0.02% bromophenol 
blue. They were separated by electrophoresis in 4–15% gradient gels fol-
lowed by electrotransfer to a nitrocellulose membrane, which was then 
probed using a polyclonal antibody (1:1,000; Cell Signaling Technology) 
that detects phosphorylated Thr
202/Tyr
204 forms of p44/42 MAPKs 
(Erk1/2). Bound antibody was detected using peroxidase-conjugated anti–
rabbit antibody (1:2,000; Bio-Rad Laboratories) followed by visualization 
using SuperSignal chemiluminescent substrate for HRP detection (Pierce 
Chemical Co.). To ensure equal protein loading, membranes were stripped 
and reprobed using polyclonal antibodies against total Erk1/2. In a sepa-
rate experiment, a subset of wells was treated with 0.5 mU/ml heparinase 
during the periods of serum starvation and growth factor stimulation. For 
Akt signaling, membranes were probed using 1:1,000 anti-phospho 
(Ser
473)-Akt monoclonal antibody (Cell Signaling Technology). The bands 
were quantiﬁ  ed by measurement of band intensity relative to background 
on a densitometer (GS800; Bio-Rad Laboratories).
Apoptosis assay on reconstituted extracellular matrix
Mutant cells were generated by transfection of subconﬂ  uent Ndst1
f/fTekCre
− 
primary murine lung endothelia with Adenoviral-Cre (Ad-Cre; UCSD Gene 
Therapy Core) at 10
9 pfu/ml for 1.5 h in normal culture growth medium. 
Infection with Adenoviral-GFP (Ad-GFP) was used as a control. Cells were 
added to Matrigel-coated wells in chamber slides. Permeabilization and 
TUNEL labeling were performed directly on chamber slides according to 
the manufacturer’s instructions (In Situ Cell Death Detection kit; Roche), and 
samples were stained with Vector Blue Alkaline Phosphatase Substrate kit 
(Vector Laboratories) and nuclear fast red stain.
Statistics
Mean values of tumor volume, microvascular density on tumor sections or 
wound sections, microvascular skeletal length, caliber, grid intersection, 
and branching, and mean relative sprouting responses on extracellular 
matrix, were compared using one-tailed t tests. P < 0.05 was considered 
signiﬁ  cant. Comparison of wound contraction rates in mutant versus wild-
type mice was performed using a two-factor repeated-measures analysis 
of variance, testing for group differences in the change over time (SPSS 
Software v. 13.0).
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